Application of Mechanistic Ocular Absorption Modeling and Simulation to Understand the Impact of Formulation Properties on Ophthalmic Bioavailability in Rabbits: a Case Study Using Dexamethasone Suspension.
bioequivalence
dexamethasone
ocular PBPK
particle size
simulation
viscosity
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
20 05 2019
20 05 2019
Historique:
received:
29
10
2018
accepted:
11
04
2019
entrez:
22
5
2019
pubmed:
22
5
2019
medline:
24
3
2020
Statut:
epublish
Résumé
Developing mathematical models to predict changes in ocular bioavailability and pharmacokinetics due to differences in the physicochemical properties of complex topical ophthalmic suspension formulations is important in drug product development and regulatory assessment. Herein, we used published FDA clinical pharmacology review data, in-house, and literature rabbit pharmacokinetic data generated for dexamethasone ophthalmic suspensions to demonstrate how the mechanistic Ocular Compartmental Absorption and Transit model by GastroPlus™ can be used to characterize ocular drug pharmacokinetic performance in rabbits for suspension formulations. This model was used to describe the dose-dependent (0.01 to 0.1%) non-linear pharmacokinetic in ocular tissues and characterize the impact of viscosity (1.67 to 72.9 cP) and particle size (5.5 to 22 μm) on in vivo ocular drug absorption and disposition. Parameter sensitivity analysis (hypothetical suspension particle size: 1 to 10 μm, viscosity: 1 to 100 cP) demonstrated that the interplay between formulation properties and physiological clearance through drainage and tear turnover rates in the pre-corneal compartment drives the ocular drug bioavailability. The quick removal of drug suspended particles from the pre-corneal compartment renders the impact of particle size inconsequential relative to viscosity modification. The in vivo ocular absorption is (1) viscosity non-sensitive when the viscosity is high and the impact of viscosity on the pre-corneal residence time reaches the maximum physiological system capacity or (2) viscosity sensitive when the viscosity is below a certain limit. This study reinforces our understanding of the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug PK performance in rabbits.
Identifiants
pubmed: 31111305
doi: 10.1208/s12248-019-0334-x
pii: 10.1208/s12248-019-0334-x
doi:
Substances chimiques
Ophthalmic Solutions
0
Suspensions
0
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
65Références
J Pharm Sci. 1976 Dec;65(12):1816-22
pubmed: 1032669
J Pharm Pharmacol. 1976 Mar;28(3):210-8
pubmed: 6695
J Pharm Sci. 1975 Aug;64(8):1312-6
pubmed: 1151703
J Pharm Sci. 1998 Dec;87(12):1479-88
pubmed: 10189253
J Pharm Sci. 2019 Jan;108(1):620-629
pubmed: 30385283
Adv Drug Deliv Rev. 2018 Feb 15;126:23-43
pubmed: 29247767
J Pharm Sci. 1979 Apr;68(4):435-43
pubmed: 438963
J Ocul Pharmacol Ther. 2008 Jun;24(3):301-8
pubmed: 18476800
Drug Metab Dispos. 1999 Nov;27(11):1350-9
pubmed: 10534321
J Pharm Sci. 1978 May;67(5):603-6
pubmed: 641790
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):215-26
pubmed: 25603198
Adv Drug Deliv Rev. 2006 Nov 15;58(11):1258-68
pubmed: 17079049
Pharm Res. 2016 Nov;33(11):2680-90
pubmed: 27431864
Drug Metab Dispos. 2015 Nov;43(11):1823-37
pubmed: 26296709
Invest Ophthalmol Vis Sci. 1993 Jun;34(7):2251-9
pubmed: 8505206
J Pharm Sci. 1980 Apr;69(4):391-4
pubmed: 7373531
J Pharm Sci. 1986 Mar;75(3):280-7
pubmed: 3701612
Pharm Res. 2018 May 31;35(8):153
pubmed: 29855726
J Pharmacol Toxicol Methods. 2019 Mar - Apr;96:9-14
pubmed: 30552958
Clin Ophthalmol. 2016 Dec 07;10:2433-2441
pubmed: 27994437
J Pharm Sci. 2012 Aug;101(8):2976-88
pubmed: 22581751
Pharm Res. 1993 Sep;10(9):1308-14
pubmed: 8234168
Eur J Pharm Sci. 2000 May;10(3):195-204
pubmed: 10767597
Mol Pharm. 2017 Aug 7;14(8):2690-2696
pubmed: 28631484
AAPS J. 2016 Jul;18(4):1032-8
pubmed: 27184578